Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Nucleic Acids Research|August 15, 2018
Structural basis for the synergy of 4'- and 2'-modifications on siRNA nuclease resistance, thermal stability and RNAi activityJoel M Harp, Dale C Guenther, Anna Bisbe, et al.
Journal of the American Chemical Society|October 7, 2024
Single-Stranded Hairpin Loop RNAs (loopmeRNAs) Potently Induce Gene Silencing through the RNA Interference PathwayKrishna C Aluri, Dhrubajyoti Datta, Scott Waldron, et al.
Nucleic Acids Research|March 15, 2020
Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5'-exonucleasePawan Kumar, Rohan Degaonkar, Dale C Guenther, et al.
Nucleic Acids Research|September 29, 2025
Modified unlocked nucleic acid (MUNA) mitigates off-target effects of small interfering RNAsShohei Mori, Dhrubajyoti Datta, Lydia Perkins, et al.
The Journal of Organic Chemistry|September 17, 2013
Identification and characterization of second-generation invader locked nucleic acids (LNAs) for mixed-sequence recognition of double-stranded DNASujay P Sau, Andreas S Madsen, Peter Podbevsek, et al.
Journal of the American Chemical Society|August 3, 2022
Role of a "Magic" Methyl: 2'-Deoxy-2'-α-F-2'-β-<i>C</i>-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5'-Phosphate Mimics and Mitigation of Off-Target EffectsDale C Guenther, Shohei Mori, Shigeo Matsuda, et al.
Nucleic Acids Research|September 11, 2021
Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencingHartmut Jahns, Rohan Degaonkar, Peter Podbevsek, et al.
Journal of Cutaneous Medicine and Surgery|August 12, 2023
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, et al.
The British Journal of Dermatology|September 4, 2020
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trialA Blauvelt, C Leonardi, B Elewski, et al.
Journal of the American Chemical Society|September 23, 2017
4'-C-Methoxy-2'-deoxy-2'-fluoro Modified Ribonucleotides Improve Metabolic Stability and Elicit Efficient RNAi-Mediated Gene SilencingElise Malek-Adamian, Dale C Guenther, Shigeo Matsuda, et al.
Pageof 10